Background: The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). Methods: Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks. Primary outcomes included HbA1c levels, intrahepatic fat (IHF) content, and liver function. Results: Both HbA1c levels and IHF content were reduced after treatment in all three groups. However, HbA1c levels were lower in the liraglutide-and metformin-treated groups than in the gliclazide-treated group, and reductions in IHF content were greater with liraglutide than with gliclazide. Liraglutide and metformin treatments reduced weight and improved liver function. Changes in IHF content were positively correlated with reductions in serum alanine aminotransferase and triglyceride levels, as well as weight. At 24 weeks, reductions in IHF content were greater in subjects with weight loss ≥5%, changes in waistline ≤0 cm (including decreases in waistline), HbA1c reductions ≥2.5%, and HbA1c levels <6.5%. Conclusions: In T2DM patients with NAFLD, compared with liraglutide and metformin, gliclazide resulted in less improvement in liver function, reductions in IHF content and HbA1c levels, and less weight loss; in addition, slightly better improvements were achieved with liraglutide than with metformin.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease worldwide. Its overall global prevalence is approximately 25% in the adult population and 50-70% in patients with obesity and type 2 diabetes mellitus (T2DM). [1] [2] [3] [4] In recent decades, the prevalence of NAFLD and T2DM in China has increased gradually to levels seen in Western countries. 4, 5 Nonalcoholic fatty liver disease is a risk factor for cirrhosis and hepatocellular carcinoma. 6, 7 Furthermore, T2DM patients with NAFLD have poorer glycemic control and develop cardiovascular disease more readily than those without NAFLD. 8, 9 Consequently, treatments focusing on both T2DM and NAFLD may be better for these patients.
The known association between patients with obesity and T2DM and NAFLD provides an opportunity to develop clinical interventions. To date, lifestyle modifications resulting in 5-10% weight loss have been effective in improving insulin resistance and inhibiting NAFLD and T2DM progression; however, only a minority of patients can adhere to diet and exercise modifications long term. [10] [11] [12] Weight loss-inducing antidiabetic drugs have been found to concomitantly alleviate hepatic steatosis. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Metformin, a biguanide, has been proposed as effective for NAFLD treatment in animal and clinical studies. 13, 14 However, randomized trials in T2DM patients showed that metformin has a neutral effect on liver fat infiltration. [15] [16] [17] Non-invasive evaluation by proton magnetic resonance spectroscopy ( 1 H-MRS) or invasive evaluation via liver biopsies in T2DM subjects with NAFLD have shown that the glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) liraglutide and exenatide significantly improved abnormal liver transaminases, biomarkers, and hepatic steatosis. [18] [19] [20] [21] [22] In these patients, weight loss was attributable to appetite suppression and changes in gastrointestinal peristaltic movement. [18] [19] [20] [21] [22] Sulfonylureas (SUs) that promote pancreatic secretion of insulin do not decrease hepatic steatosis, likely because patients treated with SUs exhibit weight gain. Thiazolidinedione, a peroxisome proliferator-activated receptor (PPAR) γ agonist, improved hyperglycemia and histology in liver biopsy (LB)-confirmed non-alcoholic steatohepatitis (NASH) patients with T2DM or impaired glucose tolerance (IGT). 15, 17, 22, 23 However, its adverse effects, especially weight gain and edema, have severely restricted its use.
Invasive assessment (e.g. LB) and non-invasive methods (such as 1 H-MRS and chemical shift-encoded magnetic resonance imaging) are gold-standard methods for hepatic steatosis quantification, but their application is restricted in general clinical practice owing to practical and technological issues. 24, 25 Ultrasonography is generally believed to have limited sensitivity in defining steatosis of <20% and in subjects with a body mass index (BMI) >40 kg/m 2 . 10 In previous studies, the results of quantitative ultrasonography using computer-aided measurement of intrahepatic fat (IHF) were confirmed to be strongly and positively correlated with 1 H-MRS results and so we considered our quantitative ultrasonography method to be a valid strategy for estimating IHF. [26] [27] [28] Until now, few studies have comparatively investigated the effects of commonly used oral SUs on IHF in T2DM patients with NAFLD. Therefore, in the present study we compared the effects of the SU gliclazide on IHF with those of liraglutide and metformin in T2DM patients with NAFLD.
Methods

Participants
Patients with T2DM and NAFLD were recruited from Drum Tower Hospital Affiliated to Nanjing University Medical School. Inclusion criteria were as follows: hypoglycemic drug naivety of ≥3 months prior to inclusion; age 18-70 years; HbA1c 7.0-14.0%; BMI 20-38 kg/m 2 ; weight fluctuations <10% within the previous 3 months; and IHF ≥10% (quantified by the standardized ultrasonography hepatic/renal [H/R] ratio and hepatic attenuation rate methods of Xia et al.) [26] [27] [28] The exclusion criteria were as follows: treatment with drugs that affect hepatic steatosis; a history of pancreatic diseases or severe gastrointestinal disease; known allergies to the test drugs; abnormal liver function (serum aspartate aminotransferase [AST] ≥2.5-fold the upper limit of normal) or moderate-to-severe renal insufficiency (estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m 2 , calculated by the modification of diet in renal disease [MDRD] equation); excessive consumption of alcohol (>14 drink units/week for women, >21 drink units/week for men); a history of autoimmune liver disease or viral hepatitis, medullary thyroid carcinoma, and multiple endocrine neoplasia type 2; congestive heart failure (New York Heart Association Grades III-IV) or other severe concomitant diseases; and pregnancy or planning to become pregnant. Informed written consent was obtained from all subjects. The study protocol was approved by the Research Ethics Board of Drum Tower Hospital Affiliated to Nanjing University Medical School (Protocol: AF/SQ-2014-026-02). This trial is registered with Clinicaltrials.gov (ID: NCT03068065).
Protocol
The present study was a single-center open-label prospective randomized trial using a parallel design and lasting 24 weeks. Following enrollment, eligible participants were randomized (1:1:1) using computergenerated random numbers to the metformin (Glucophage; Bristol-Myers Squibb, New York, NY, USA), liraglutide (Victoza; Novo Nordisk, Bagsvaerd, Denmark), or gliclazide (Diamicron; Servier, Paris, France) groups. All patients were informed about proper diet and exercise. For the metformin group (n = 31), the dosage was 250 mg thrice daily during the first week, 500 mg thrice daily during the second week, and 1000 mg twice daily from the third week to the conclusion of the study. For the gliclazide group (n = 31), the initial dosage was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/ day to achieve a fasting capillary plasma glucose level of <7.0 mmol/L. For the liraglutide group (n = 31), the dosage was 0.6 mg/day during the first week, 1.2 mg/ day during the second week, and 1.8 mg/day from the third week to the conclusion of the study.
Measurements
Evaluation of IHF by ultrasonography The IHF content was assessed at baseline and at the end of the study by ultrasonography using a quantitative assessment method and standardized ultrasonography H/R ratio and hepatic attenuation rate, as described previously. 26 Liver and kidney ultrasonography was performed using a GE LOGIQ 7 ultrasound machine (GE Healthcare, Horten, Norway) equipped with a GE 3.5 CS curved array transducer (GE H4904PC) by an experienced radiologist who was blinded to the patients' clinical details and laboratory findings. All instrument settings, including depth, gain, and time-gain compensation, were corrected by a fatty liver standard module and fixed for the study duration. A view of the sagittal liver/right kidney was obtained under the lateral position for ultrasonography H/R ratio assessment. The ultrasonography hepatic echointensity attenuation rate was evaluated in the right intercostal view at the anterior axilla line in patients in the supine position. National Institutes of Health (Bethesda, MD, USA) imaging software (IMAGEJ 1.41o) was used to analyze digitized ultrasound images.
Standard meal tolerance test and evaluation of blood glucose, blood biochemistry, HbA1c, and body composition All subjects underwent a repeated standard meal tolerance test by ingesting 85 g of carbohydrate equivalent instant noodles at baseline and after 24 weeks of drug intervention. Plasma glucose and insulin were measured at 0, 30, 60, and 120 min after ingestion of the meal. Participants returned to the Clinical Research Center at 0800 hours following an overnight fast at the end of Weeks 2 and 4 and then every 4 weeks for a total of seven visits to measure body weight, waistline, blood pressure, fasting blood glucose (FBG), and postprandial blood glucose (PBG) after taking the respective drugs and eating breakfast. 
Statistical analysis
All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) on an intention-to-treat basis. Quantitative variables are presented as the mean AE SEM. One-way analysis of Excluded (n = 23) 13 unwilling to participate 10 did not meet inclusion criteria Figure 1 Flow diagram of study participants. Of the 116 subjects recruited for the study, 13 were unwilling to participate and 10 did not meet the inclusion criteria. NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus; MR, modified release tablets. Unless indicated otherwise, data are the mean AE SEM. *P < 0.05, **P < 0.01 compared with pretreatment within each treatment group.
30-, 60-, 120-min BG, blood glucose levels at 30, 60 and 120 min, respectively, in the standard meal tolerance test; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CH, total cholesterol; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.
variance (ANOVA) with the least significant difference was used to compare group means. For assessment of variance of repeated measures data and differences between the treatment groups, repeated-measures of general linear model and multivariate progress were used. Enumeration data were analyzed by the Chisquared test. Variable differences between two groups were evaluated by Student's t-test. Correlation analyses and stepwise multiple linear regression analyses of variable relationships with changes in IHF were assessed. Two-tailed P < 0.05 was considered significant. A statistician from Drum Tower Hospital was consulted for all statistical analyses.
Results
Baseline values
Ninety-three patients (mean age 47.15 AE 1.17 years, BMI 27.57 AE 0.33 kg/m 2 , FBG 8.77 AE 0.24 mmol/L, and HbA1c 9.16 AE 0.17%) were successfully screened for study participation (n = 30, 32, and 31 in the liraglutide, gliclazide, and metformin groups, respectively). Among these patients, 29 in each group completed the 24-week treatment (Fig. 1) . Clinical characteristics, glucose levels, IHF content, and lipid profiles among the three treatment groups were similar at baseline (Table 1) .
Treatment effects on IHF content, liver function, and serum TG levels Baseline IHF was 34.92 AE 1.85%, with no significant differences among the three treatment groups (P = 0.717; Fig. 2a) . After 24 weeks of drug intervention, IHF decreased significantly in all treatment groups, from 36.70 AE 3.65% to 13.11 AE 1.84% in the liraglutide group, from 32.99 AE 3.51% to 19.59 AE 2.12% in the gliclazide group, and from 35.13 AE 2.34% to 18.44 AE 2.20% in the metformin group (P < 0.001 for all treatment groups, final vs baseline; Fig. 2a ). The reduction in IHF following liraglutide treatment was greater than that following gliclazide treatment (P = 0.001; Fig. 2b) .
Following IHF improvement, liver function improved in all treatment groups; however, liver function improvement only reached statistical significance in the metformin and liraglutide groups (Fig. 3a,b) . Serum ALT and AST levels were significantly lower after Weeks 4, 12, and 24 of liraglutide treatment than at baseline. Alanine aminotransferase levels were significantly lower at the end of Weeks 12 and 24 of liraglutide treatment than at the end of Week 4. Alanine aminotransferase and AST levels were significantly lower after Weeks 4, 12, and 24 of metformin treatment than at baseline. Further, ALT levels were significantly lower after 12 weeks of metformin treatment than after 4 weeks of treatment.
Serum TG levels were lower in patients receiving all three treatments at Weeks 4, 12, and 24 than at baseline (Fig. 3c) .
Weight loss and body composition
Body weight decreased in all three treatment groups; however, changes in body weight reached significance only in the liraglutide and metformin groups (body weight change −5.60 AE 0.79 [P < 0.001] and −3.58 AE 0.91 kg [P = 0.001], respectively; Table 1 ). Similarly, BMI decreased markedly in the liraglutide and metformin groups, but not in the gliclazide group (Table 1) . Waistline decreased significantly in the liraglutide and metformin groups, whereas no change was observed in waistline in the gliclazide group (Table 1) . 
Glucose levels and HbA1c
There were no significant differences among the three treatment groups in blood glucose levels at baseline, and at 0, 30, 60, and 120 min in the standard meal tolerance test (Table 1) . However, after 24 weeks treatment, blood glucose levels at 0, 30, 60, and 120 min in the standard meal tolerance test were significantly lower than the baseline level for all three treatment groups (P < 0.001 for all groups). Blood glucose levels were lower in the liraglutide group than in the gliclazide and metformin groups at 30 and 60 min. At 120 min, blood glucose levels were lower in the liraglutide and metformin groups than in the gliclazide group (Fig. 4a ).
There were no remarkable differences in HbA1c between the treatment groups at baseline. However, after intervention, HbA1c decreased significantly among all three treatment groups by Weeks 12 and 24 (HbA1c changes at Weeks 12 and 24 of −2.9 AE 0.3% and −3.0 AE 0.4%, respectively, for liraglutide [P < 0.001]; −2.5 AE 0.3% and −2.6 AE 0.3%, respectively, for gliclazide [P < 0.001]; −3.1 AE 0.4% and −3.3 AE 0.4%, respectively, for metformin [P < 0.001]; Fig. 4b ). At Weeks 12 and 24, HbA1c was higher in the gliclazide group than in the liraglutide group (P = 0.001 and P = 0.002, respectively), and was higher in the gliclazide than metformin group at Week 24 (P = 0.014; Fig. 4c ).
Correlation analyses
Weight reduction was significantly correlated with changes in IHF for all subjects, both before and after adjusting for BMI (Table 2 ). To explicitly determine the contributions of weight loss to changes in IHF, all patients were divided into two subgroups according to the amount of weight lost: ≥5% and <5%. Reductions in IHF were greater in patients who achieved more weight loss than in those with less weight loss (Fig. 5a) . Relative TG and ALT changes were both significantly correlated with IHF changes for all subjects before and after adjusting for BMI (Table 2 ). In addition, baseline IHF was significantly correlated with relative changes in IHF for all three treatment groups ( Table 2) . Changes in IHF were greater in patients with stable waistline or whose waistline decreased after treatment compared with those with increased waistline (Fig. 5b) . In patients whose HbA1c decreased by ≥2.5%, reductions in IHF were more significant than in those whose HbA1c decreased by <2.5% (Fig. 5c) . Patients with HbA1c <6.5% at Week 24 had a markedly lower IHF content than patients with HbA1c ≥6.5% (Fig. 5d) .
Discussion
The present study was a systematic and comparative evaluation of changes in IHF in T2DM patients with NAFLD randomly assigned to receive liraglutide, gliclazide, or metformin monotherapy. As expected, IHF content was reduced by the GLP-1 analog liraglutide, as well as the biguanide metformin, both of which have been shown to be IHF-lowering antidiabetic drugs. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] However, of importance is the finding that gliclazide, an SU, also lowered IHF content. Generally, IHF content is thought to be unchanged by gliclazide. Liraglutide reduced IHF content to a greater extent than gliclazide did after 24 weeks of treatment. Levels of ALT and AST, indicators of NAFLD, decreased following liraglutide and metformin treatment, but not after gliclazide treatment. Serum TG levels decreased in all three treatment groups.
Weight gain is a crucial factor in T2DM and NAFLD development, [1] [2] [3] [4] [5] whereas weight loss results in decreased liver fat. [10] [11] [12] Hepatic steatosis has been shown to be significantly reduced by lifestyle changes, treatment with GLP-1 analogs, metformin, or bariatric surgery interventions when significant reductions in body weight were achieved; [14] [15] [16] [18] [19] [20] [21] [22] [23] these reports are supported by results in the liraglutide and metformin intervention groups in the present study. Weight loss was greater in the liraglutide and metformin groups Figure 5 Changes in intrahepatic fat (IHF) from baseline in patients stratified according to (a) weight loss (≥5% and <5%), (b) changes in waistline (≤0 and >0 cm), (c) reductions in HbA1c (≥2.5% and <2.5%), and HbA1c levels (<6.5% and ≥6.5%) at Week 24. There decrease in IHF was significant greater for patients with greater weight loss, those with a ≤0 cm change in waistline, and those with a greater reduction in HbA1c. Data are the mean AE SEM. *P < 0.01, **P < 0.01.
than in the gliclazide group after 2 weeks treatment, an effect that became more prominent as the treatment period was extended. In line with previous studies, 22 we found weight loss to be positively correlated with reductions in IHF content before and after adjusting for BMI. The linear regression equation for the relationship between changes in IHF and weight reduction showed that greater weight loss (weight loss ≥5%) resulted in a greater decrease in IHF content than less weight loss (weight loss <5%). These results suggest that weight loss has a pivotal role in reducing hepatic fat. Aggressive treatment for weight loss by metformin and liraglutide may be beneficial for decreasing IHF content. There were fewer hypoglycemic events observed in the present study for the gliclazide group than reported for other SU drugs, 29 likely resulting in patients being less likely to overeat. No weight gain was observed in gliclazidetreated patients in the present study, which may eliminate harmful effects on IHF content.
Increasing waistline is related to increased body weight, which contributes to central obesity and is an independent risk factor for NAFLD and T2DM. 30, 31 In the present study, waistline only decreased in the liraglutide and metformin groups. In the present study, a greater reduction in IHF was achieved in patients with stable or decreased waistline than in patients with increased waistline, which may explain, in part, the difference in IHF reduction observed in the liraglutide and metformin groups compared with the gliclazide group.
Increased blood glucose and high IHF are correlated. A previous study showed that changes in IHF are closely associated with changes in HbA1c; alleviation of glucose toxicity is crucial to IHF reduction. 2, 22 In the present study, liraglutide, gliclazide, and metformin monotherapy reduced HbA1c and FBG levels. Reductions in blood glucose levels at 30, 60, and 120 min during the standard meal tolerance test were associated with a 34% reduction in IHF after gliclazide treatment for 24 weeks. The short-acting insulin secretagog nateglinide improved liver histology in NASH patients.
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Insulin has been shown to decrease IHF in drug-naïve subjects with T2DM. 22 These findings suggest that alleviation of glucose toxicity plays a part in improving liver fat deposition.
Decreases in HbA1c ≥2.5% were associated with greater reductions in IHF than decreases in HbA1c <2.5% for all treatment groups. Significantly greater IHF reductions were achieved in patients with HbA1c <6.5% at Week 24 than in patients with HbA1c ≥6.5% at Week 24, suggesting that better glycemic control results in greater reductions in IHF. The three treatments were found to be effective in reducing HbA1c in the following order: liraglutide > metformin > gliclazide.
Blood glucose levels in the standard meal tolerance test at 30, 60, and 120 min in the liraglutide group and at 120 min in the metformin group were lower than those in the gliclazide group. More efficient blood glucose control, as observed in the metformin and liraglutide groups, may more efficiently reduce IHF content. These results suggest that controlling hyperglycemia may facilitate NAFLD amelioration. 22 Alanine aminotransferase and AST levels decreased in the liraglutide and metformin groups, but not in the gliclazide group, suggesting that a >50% IHF reduction in NAFLD may improve liver function. Non-alcoholic fatty liver disease is associated with increased serum TG concentrations, independent of other obesity measures. 1 Aggressive interventions targeting hypertriglyceridemia led to inconsistent effects on fatty liver.
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Decreased serum TG was associated with alleviation of hepatic steatosis in all three treatment groups in the present study.
The majority of adverse events reported in the liraglutide and metformin groups were gastrointestinal related; however, no patients dropped out of the study because of these adverse events. In the liraglutide group, patients experienced appetite suppression (n = 22), nausea (n = 3), diarrhea (n = 4), abdominal distension (n = 3), and a temporary rash at the injection site (n = 1). In the metformin group, patients experienced appetite suppression (n = 6), nausea (n = 4), diarrhea (n = 10), abdominal distension (n = 5), and a mild hypoglycemic reaction (n = 2). Two patients in the gliclazide group had a mild hypoglycemic reaction that was relieved by a dosage reduction.
The present study has several limitations. First, the study sample size is small. Second, we did not use 1 H-MRS, which is the gold standard for evaluating IHF, because of budgetary constraints.
In summary, liraglutide and metformin monotherapy ameliorated liver aminotransferase levels, alleviated hyperglycemia, and reduced IHF, body weight, and waistline to a greater extent than gliclazide in T2DM patients with NAFLD. The liraglutide group had slightly better results than the metformin group. Reductions in IHF were associated with greater weight loss, no increase in waistline, and lower HbA1c.
